AVAI BIO, INC.
AI Executive Summary
AI-powered analysis of 10-Q filing content
AVAI BIO shows severe financial distress with negative stockholders' equity of $2.8M, zero revenue, and deteriorating liquidity. Cash declined 38% to just $50k while total liabilities increased 66% to $3M, creating an immediate going concern risk for this pre-revenue biotech company.
Red Flags Detected (7)
Stockholders' deficit of $2,794,486 vs $1,563,872 prior - 78% deterioration
Cash position critically low at $50,402, down 38% from $81,053
Zero revenue with $1.4M operating expenses in 9 months
4 more red flags detected
Key Takeaways
Company is pre-revenue biotech burning through cash rapidly
Negative working capital of $2.9M creates immediate viability concerns
3 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.